Skip to main content
SpringerLink
Log in

BRAVE Initiative review finds vaccine HTAs often omit broader elements of value

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The countries included Belgium, Canada, France, Germany, Italy, Japan, UK and the USA.

Reference

  • Bell E, et al. Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward. Applied Health Economics and Health Policy : 1-13, 23 Sep 2021. Available from: URL: http://doi.org/10.1007/s40258-021-00683-z

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

BRAVE Initiative review finds vaccine HTAs often omit broader elements of value. PharmacoEcon Outcomes News 889, 3 (2021). https://doi.org/10.1007/s40274-021-08091-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08091-8

Search

Navigation